U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 1481

1.
The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs
Daria A. Bogdanova, Ekaterina D. Kolosova, Tamara V. Pukhalskaia, Ksenia A. Levchuk, Oleg N. Demidov, Ekaterina V. Belotserkovskaya
Int J Mol Sci. 2024 Apr; 25(7): 4031. Published online 2024 Apr 4. doi: 10.3390/ijms25074031
PMCID:
PMC11012227
ArticlePDF–1.8M
2.
New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies
Wael A. A. Fadaly, Taha H. Zidan, Nesma M. Kahk, Fatma E. A. Mohamed, Marwa M. Abdelhakeem, Rehab G. Khalil, Mohamed T. M. Nemr
J Enzyme Inhib Med Chem. 2023; 38(1): 2281262. Published online 2023 Nov 27. doi: 10.1080/14756366.2023.2281262
PMCID:
PMC11003491
ArticlePDF–5.2M
3.
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
Simone Claudiani, Farhan Chughtai, Afzal Khan, Chloe Hayden, Fiona Fernando, Jamshid Khorashad, Victoria Orovboni, Glenda Scandura, Andrew Innes, Jane F. Apperley, Dragana Milojkovic
Leukemia. 2024; 38(4): 796–802. Published online 2024 Feb 29. doi: 10.1038/s41375-024-02187-w
PMCID:
PMC10997507
ArticlePDF–997K
4.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Satu Mustjoki, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Leukemia. 2024; 38(4): 781–787. Published online 2024 Jan 26. doi: 10.1038/s41375-024-02145-6
Correction in:
Leukemia. 2024; 38(4): 925.
PMCID:
PMC10997502
ArticlePDF–1.0M
5.
Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data
Franziska Meiners, Burkhard Hinz, Lars Boeckmann, Riccardo Secci, Salem Sueto, Lars Kuepfer, Georg Fuellen, Israel Barrantes
Sci Rep. 2024; 14: 6286. Published online 2024 Mar 15. doi: 10.1038/s41598-024-55870-4
PMCID:
PMC10943199
ArticlePDF–1.2M
6.
Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions
Edwin Lee, Natàlia Carreras-Gallo, Leilani Lopez, Logan Turner, Aaron Lin, Tavis L. Mendez, Hannah Went, Alan Tomusiak, Eric Verdin, Michael Corley, Lishomwa Ndhlovu, Ryan Smith, Varun B. Dwaraka
Aging (Albany NY) 2024 Feb 28; 16(4): 3088–3106. Published online 2024 Feb 22. doi: 10.18632/aging.205581
PMCID:
PMC10929829
ArticlePDF–1.6M
7.
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
Robin Foà, Renato Bassan, Loredana Elia, Alfonso Piciocchi, Stefano Soddu, Monica Messina, Felicetto Ferrara, Monia Lunghi, Antonino Mulè, Massimiliano Bonifacio, Nicola Fracchiolla, Prassede Salutari, Paola Fazi, Anna Guarini, Alessandro Rambaldi, Sabina Chiaretti
J Clin Oncol. 2024 Mar 10; 42(8): 881–885. Published online 2023 Dec 21. doi: 10.1200/JCO.23.01075
PMCID:
PMC10927329
ArticlePDF–612K
8.
Underlying Mechanisms and Treatment of Cellular Senescence-Induced Biological Barrier Interruption and Related Diseases
Ruize Sun, Juan Feng, Jue Wang
Aging Dis. 2024 Apr 1; 15(2): 612–639. Published online 2024 Apr 1. doi: 10.14336/AD.2023.0621
PMCID:
PMC10917536
ArticlePDF–825K
9.
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Tove Selvin, Malin Berglund, Lena Lenhammar, Magnus Lindskog, Malin Jarvius, Rolf Larsson, Peter Nygren, Mårten Fryknäs, Claes R Andersson
BMC Pharmacol Toxicol. 2024; 25: 25. Published online 2024 Mar 5. doi: 10.1186/s40360-024-00746-6
PMCID:
PMC10913607
ArticlePDF–2.8M
10.
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Dehua Zhao, Xiaoqing Long, Jisheng Wang
BMC Pharmacol Toxicol. 2024; 25: 20. Published online 2024 Feb 23. doi: 10.1186/s40360-024-00741-x
PMCID:
PMC10885429
ArticlePDF–1.3M
11.
Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors
Julia Krushkal, Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker, Ralph E. Parchment, Lisa M. McShane, James H. Doroshow
Epigenetics. 2024; 19(1): 2309824. Published online 2024 Feb 18. doi: 10.1080/15592294.2024.2309824
PMCID:
PMC10878021
ArticlePDF–1.8M
12.
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
Mitzi M. Gonzales, Valentina R. Garbarino, Tiffany F. Kautz, Juan Pablo Palavicini, Marisa Lopez-Cruzan, Shiva Kazempour Dehkordi, Julia J. Mathews, Habil Zare, Peng Xu, Bin Zhang, Crystal Franklin, Mohamad Habes, Suzanne Craft, Ronald C. Petersen, Tamara Tchkonia, James L. Kirkland, Arash Salardini, Sudha Seshadri, Nicolas Musi, Miranda E. Orr
Nat Med. Author manuscript; available in PMC 2024 Feb 19.
Published in final edited form as: Nat Med. 2023 Oct; 29(10): 2481–2488. Published online 2023 Sep 7. doi: 10.1038/s41591-023-02543-w
PMCID:
PMC10875739
ArticlePDF–850K
13.
Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression
Yujiao Deng, Zhanwu Hou, Yizhen Li, Ming Yi, Ying Wu, Yi Zheng, Fei Yang, Guansheng Zhong, Qian Hao, Zhen Zhai, Meng Wang, Xiaobin Ma, Huafeng Kang, Fanpu Ji, Chenfang Dong, Huadong Liu, Zhijun Dai
Cell Commun Signal. 2024; 22: 115. Published online 2024 Feb 12. doi: 10.1186/s12964-024-01487-z
PMCID:
PMC10860301
ArticlePDF–13M
14.
Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway
Xinwang Zhu, Congxiao Zhang, Linlin Liu, Li Xu, Li Yao
Int J Mol Med. 2024 Mar; 53(3): 26. Published online 2024 Jan 17. doi: 10.3892/ijmm.2024.5350
PMCID:
PMC10852012
ArticlePDF–8.0M
15.
Flavonoid 4,4′-dimethoxychalcone selectively eliminates senescent cells via activating ferritinophagy
Tianxiang Wang, Changmei Yang, Zhiqiang Li, Ting Li, Ran Zhang, Yujiao Zhao, Tianyi Cheng, Zhaoyun Zong, Yingying Ma, Dongyuan Zhang, Haiteng Deng
Redox Biol. 2024 Feb; 69: 103017. Published online 2023 Dec 30. doi: 10.1016/j.redox.2023.103017
PMCID:
PMC10791569
ArticlePDF–8.4M
16.
Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study
Cih-En Huang, Kuan-Der Lee, Jung-Jung Chang, Huey-En Tzeng, Shih-Hao Huang, Lennex Hsueh-Lin Yu, Min-Chi Chen
Oncologist. 2024 Jan; 29(1): e81–e89. Published online 2023 Aug 10. doi: 10.1093/oncolo/oyad225
PMCID:
PMC10769786
ArticlePDF–721K
17.
Human Rotator Cuff Tears Reveal an Age-Dependent Increase in Markers of Cellular Senescence and Selective Removal of Senescent Cells With Dasatinib + Quercetin Increases Genetic Expression of COL1A1 In Vitro
Benjamin C. Hawthorne, Ian J. Wellington, Joshua T. Sabitsky, Kyle V. Murphy, Owen P. Karsmarski, Rohin O. Thomas, Matthew R. LeVasseur, Michael R. Mancini, Maxwell T. Trudeau, Sagar Gulati, Mary Beth R. McCarthy, Mark P. Cote, Ming Xu, Augustus D. Mazzocca
Arthroscopy. Author manuscript; available in PMC 2024 Feb 16.
Published in final edited form as: Arthroscopy. 2024 Jan; 40(1): 34–44. Published online 2023 Jun 23. doi: 10.1016/j.arthro.2023.05.036
PMCID:
PMC10746834
ArticlePDF–600K
18.
The Role of Cellular Senescence in Cyclophosphamide-Induced Primary Ovarian Insufficiency
Zixin Xu, Nozomi Takahashi, Miyuki Harada, Chisato Kunitomi, Akari Kusamoto, Hiroshi Koike, Tsurugi Tanaka, Nanoka Sakaguchi, Yoko Urata, Osamu Wada-Hiraike, Yasushi Hirota, Yutaka Osuga
Int J Mol Sci. 2023 Dec; 24(24): 17193. Published online 2023 Dec 6. doi: 10.3390/ijms242417193
PMCID:
PMC10743614
ArticlePDF–3.1M
19.
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice
Shun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, Noriyoshi Iriyama, Yuta Kimura, Eisaku Iwanaga, Kei-ji Sugimoto, Toru Mitsumori, Maho Ishikawa, Tomonori Nakazato, Hiroyuki Fujita, Eriko Sato, Yoshihiro Hatta, Norio Asou, Masahiro Kizaki, Michihide Tokuhira, Miki Ando, Tatsuya Kawaguchi
Intern Med. 2023 Nov 15; 62(22): 3299–3303. Published online 2023 Mar 31. doi: 10.2169/internalmedicine.1611-23
PMCID:
PMC10713361
ArticlePDF–181K
20.
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans
Jiří Hofmann, Aleš Bartůněk, Tomáš Hauser, Gregor Sedmak, Josef Beránek, Pavel Ryšánek, Martin Šíma, Ondřej Slanař
Leukemia. 2023; 37(12): 2486–2492. Published online 2023 Oct 3. doi: 10.1038/s41375-023-02045-1
PMCID:
PMC10681895
ArticlePDF–727K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center